Abbrea Capital LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,420 shares of the biopharmaceutical company’s stock after buying an additional 1,274 shares during the quarter. Abbrea Capital LLC’s holdings in Pfizer were worth $2,337,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. BlackRock Inc. increased its position in Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after buying an additional 6,785,335 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in Pfizer by 0.3% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 61,881,280 shares of the biopharmaceutical company’s stock valued at $2,245,053,000 after buying an additional 160,730 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Pfizer by 11.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock valued at $1,674,223,000 after buying an additional 4,998,981 shares in the last quarter. Fisher Asset Management LLC increased its position in Pfizer by 4.4% in the 2nd quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock valued at $1,431,069,000 after buying an additional 1,671,311 shares in the last quarter. Finally, LSV Asset Management increased its position in Pfizer by 2.7% in the 2nd quarter. LSV Asset Management now owns 36,774,591 shares of the biopharmaceutical company’s stock valued at $1,334,182,000 after buying an additional 973,497 shares in the last quarter. 69.01% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Laurie J. Olson sold 10,214 shares of the company’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $41.00, for a total value of $418,774.00. Following the transaction, the insider now owns 72,672 shares in the company, valued at $2,979,552. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Pfizer Inc acquired 55,556 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the purchase, the insider now owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The disclosure for this purchase can be found here. 0.06% of the stock is owned by insiders.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. Pfizer had a return on equity of 25.34% and a net margin of 44.63%. The firm had revenue of $13.30 billion for the quarter, compared to the consensus estimate of $13.53 billion. During the same quarter in the previous year, the business earned $0.67 EPS. The company’s revenue was up 1.0% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 3 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.17%. Pfizer’s payout ratio is presently 51.32%.
A number of brokerages recently commented on PFE. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a research report on Tuesday, August 28th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th. Independent Research set a $48.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Thursday, October 4th. Credit Suisse Group boosted their price objective on Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a report on Wednesday, August 1st. Finally, Barclays reissued a “neutral” rating and set a $40.00 price objective on shares of Pfizer in a report on Wednesday, September 26th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and a consensus price target of $42.95.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: S&P 500 Index
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.